ERBB2 and breast carcinoma: The NEOSPHERE, neoadjuvant trial, took patients with operable HER2 positive breast cancer (n = 417) and placed them in four arms receiving 4 cycles: docetaxel plus trastuzumab and pertuzumab, docetaxel plus trastuzumab, docetaxel plus pertuzumab, or pertuzumab plus trastuzumab without chemotherapy [27].